Free Trial
NASDAQ:INMD

InMode (INMD) Stock Price, News & Analysis

InMode logo
$17.38
+0.12 (+0.70%)
(As of 11/4/2024 ET)

About InMode Stock (NASDAQ:INMD)

Key Stats

Today's Range
$17.13
$17.49
50-Day Range
$14.88
$18.35
52-Week Range
$14.87
$26.80
Volume
1.34 million shs
Average Volume
1.34 million shs
Market Capitalization
$1.46 billion
P/E Ratio
9.39
Dividend Yield
N/A
Price Target
$22.60
Consensus Rating
Hold

Company Overview

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

InMode Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
74th Percentile Overall Score

INMD MarketRank™: 

InMode scored higher than 74% of companies evaluated by MarketBeat, and ranked 279th out of 972 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    InMode has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    InMode has only been the subject of 3 research reports in the past 90 days.

  • Read more about InMode's stock forecast and price target.
  • Earnings Growth

    Earnings for InMode are expected to grow by 22.78% in the coming year, from $1.58 to $1.94 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of InMode is 9.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.17.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of InMode is 9.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 128.68.

  • Price to Book Value per Share Ratio

    InMode has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about InMode's valuation and earnings.
  • Percentage of Shares Shorted

    8.25% of the outstanding shares of InMode have been sold short.
  • Short Interest Ratio / Days to Cover

    InMode has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in InMode has recently decreased by 1.28%, indicating that investor sentiment is improving.
  • Dividend Yield

    InMode does not currently pay a dividend.

  • Dividend Growth

    InMode does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.25% of the outstanding shares of InMode have been sold short.
  • Short Interest Ratio / Days to Cover

    InMode has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in InMode has recently decreased by 1.28%, indicating that investor sentiment is improving.
  • News Sentiment

    InMode has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for InMode this week, compared to 7 articles on an average week.
  • Search Interest

    9 people have searched for INMD on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added InMode to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, InMode insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.92% of the stock of InMode is held by insiders.

  • Percentage Held by Institutions

    68.04% of the stock of InMode is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about InMode's insider trading history.
Receive INMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.

INMD Stock News Headlines

InMode's (INMD) Hold Rating Reaffirmed at Needham & Company LLC
InMode price target raised to $17 from $16 at Canaccord
Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
InMode: A Deep Dive After Q3 Earnings
InMode’s Q3 2024: Revenue Growth Amid Challenges
InMode Sees Revenue Growth Amidst Challenges in Q3 2024
See More Headlines

INMD Stock Analysis - Frequently Asked Questions

InMode's stock was trading at $22.24 on January 1st, 2024. Since then, INMD stock has decreased by 21.9% and is now trading at $17.38.
View the best growth stocks for 2024 here
.

InMode Ltd. (NASDAQ:INMD) posted its quarterly earnings results on Thursday, August, 1st. The healthcare company reported $0.34 earnings per share for the quarter, missing analysts' consensus estimates of $0.38 by $0.04. The business's quarterly revenue was down 24.6% on a year-over-year basis.

InMode shares split on the morning of Thursday, September 30th 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly minted shares were issued to shareholders after the closing bell on Monday, September 27th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

InMode subsidiaries include Guangzhou InMode Medical Technology Ltd., InMode Asia Limited., InMode India Private Limited, InMode Japan KK, InMode M.D. Ltd., Invasix Corp., Invasix Iberia S.L., Invasix Inc., and Invasix UK Ltd..

InMode (INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

Top institutional shareholders of InMode include Boston Trust Walden Corp (1.68%), Meitav Investment House Ltd. (1.61%), Swedbank AB (0.41%) and IMC Chicago LLC.

Shares of INMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
8/01/2024
Today
11/04/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/11/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:INMD
Fax
N/A
Employees
480
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$22.60
High Stock Price Target
$27.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+30.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$197.92 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$423.75 million
Cash Flow
$2.24 per share
Book Value
$8.77 per share

Miscellaneous

Free Float
78,170,000
Market Cap
$1.45 billion
Optionable
Optionable
Beta
2.15

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:INMD) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners